1x LITUO COVID-19 Antigen Detection Kit (Colloidal Gold) Lay Test (1 PU)

1,09 

Plus 19% VAT
(1,09  / 1 piece)
  • Self test
  • Determination by means of a nasal swab
  • Test result in 15 minutes
  • individually packaged
  • CE 1434 – lay approval

Minimum order: 500 pieces (= 1 box)
Shipping costs: € 8.20 per box

Delivery from week 49. Inquiries / pre-orders by email:

Write e-mail

Ausverkauft


SKU MHC-LITL-1 Category

Simple and safe – test result in 15 minutes

The rapid corona test from the manufacturer Zhuhai Lituo is particularly characterized by its simple and safe application. A short sterile swab is only rolled about 2 cm deep into both nostrils. A liquid is then prepared using the extraction buffer tube. 2 drops of this liquid are dripped into the enclosed test cassette. After only 15 minutes, the test shows a positive or negative result via colour stripes.

Instructions for useInstruction for use

Properties

  • Manufacturer: Zhuhai Lituo Biotechnology Co., Ltd
  • Product name: LITUO COVID-19 rapid antigen test (colloidal gold)
  • CE certified: No. 1434 | Ref. No. LCV03, LCV035, LCV03I
  • Type of sample: swab from the anterior nasal area 2 – 3cm (anterior nasal)
  • Duration of use: 15 minutes
  • Clinical sensitivity: 94.53%
  • Clinical specificity:> 99%
  • Cl 95% sensitivity: 88.80% – 97.41%
  • Cl 95% specificity: 97.93% – 99.97%
  • Packaging units: 1 piece
Statement MutationDeclaration of limit of detectionDeclaration of marketability

CE 1434 – tested

LITUO COVID-19 rapid antigen test for laypeople has a completed conformity assessment procedure and a four-digit check digit. The test thus fulfills the Europe-wide approval for sales and trading.

The LITUO rapid test has already successfully passed several different approval offices in different countries. These include, among others. America, Spain, China, Canada.

Certificates

Registration

The SARS-CoV-2 antigen test for self-use is approved in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and meets the criteria of the Paul Ehrlich Institut (PEI).

PEI: https://www.pei.de
BfArM: https://antigentest.bfarm.de

© 2021 MILA Health Care

Contact

MILA Health Care Germany GmbH
Märkische Str. 71
15806 Zossen

Tel.: +49 331 585 690 80
Fax: +49 331 585 690 99
E-Mail: vertrieb@mila-healthcare.de

Pay securely

Our offers are only addressed to entrepreneurs, §14 BGB, i.e. to natural or legal persons or partnerships with legal capacity who, when concluding a legal transaction, are acting in the exercise of their commercial or independent professional activity. We do not conclude contracts with consumers, § 13 BGB.